Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers.
A live dengue virus type 2 (dengue-2) vaccine (PR-159/S-1) was tested for reactogenicity and immunogenicity in a placebo-controlled, double-blind clinical trial involving 98 soldiers. Seroconversion rates based on the development of neutralizing antibody to dengue-2 were 90% in 70 recipients with immunity to yellow fever and 61% in 28 vaccinees without such immunity (P less than .01). Peak titers of neutralizing antibody were three times higher in recipients with antibody to yellow fever virus and persisted in most for at least 18 months. Individuals seroconverting to the vaccine virus more frequently experienced systemic symptoms than those who received placebo (P less than .02). Future users of this dengue-2 vaccine may wish to employ immunization schedules that include preliminary immunization against yellow fever and must be prepared to accept mild vaccine-related symptoms in some recipients.
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis*; D002986:Clinical Trials as Topic; D003716:Dengue Virus / Q000276:immunology* / Q000302:isolation & purification; D004311:Double-Blind Method; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D008887:Military Medicine; D009500:Neutralization Tests; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*; D015005:Yellow fever virus / Q000276:immunology
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines